

**Amendments to the Claims:**

Please cancel claims 33-36 without prejudice.

Please amend claims 18, 37, 39 and 65.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-17. (Canceled)

18. (Currently Amended) A genomic streptavidin fusion protein, comprising at least a first and a second polypeptide joined end to end, wherein said first polypeptide comprises at least 129 amino acids of streptavidin, as set forth in SEQ ID NO:2, and wherein said second polypeptide is an antibody or antigen-binding fragment of an antibody that specifically binds a cell surface protein or a cell-associated stromal matrix protein, selected from the group consisting of: CD20, CD45, EGP40, CEA, TAG72, NCAM, β-HCG, a mucin, and neoangiogenic antigens, and wherein said fusion protein is expressed as a soluble protein in the periplasmic space.

19. (Original) The fusion protein of claim 18, wherein said first and second polypeptides are separated by a linker of at least two amino acids.

20. (Original) The fusion protein of claim 19, wherein the linker is at least four amino acids.

21. (Previously Presented) The fusion protein of claim 20, wherein the linker consists of four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty amino acids.

22. (Previously Presented) The fusion protein of claim 21, wherein the linker is between five and ten amino acids.

23. (Canceled)

24. (Previously Presented) The genomic streptavidin fusion protein of claim 18, wherein said fusion protein forms a tetrameric complex with a second, third, and fourth fusion protein, said second, third, and fourth fusion protein comprising at least a first and second polypeptide joined end to end, wherein said first polypeptide comprises at least 129 amino acids of streptavidin, as set forth in SEQ ID NO:2, and wherein said second polypeptide is an antibody or antigen-binding fragment thereof.

25. (Previously Presented) The fusion protein of claim 18, wherein the antibody is B9E9.

26. (Previously Presented) The fusion protein of claim 18 wherein the antibody is a single-chain Fv fragment.

27. (Original) The fusion protein of claim 26, wherein the single-chain Fv fragment is derived from antibody B9E9.

28. (Original) The fusion protein of claim 26, wherein a linker connects the variable light and variable heavy chains of the single chain antibody.

29. (Original) The fusion protein of claim 28, wherein the linker comprises at least ten amino acid residues.

30. (Original) The fusion protein of claim 29, wherein the linker comprises at least fifteen amino acids.

31. (Original) The fusion protein of claim 30, wherein the linker comprises at least twenty amino acids.

32. (Previously Presented) The fusion protein of claim 31, wherein the linker comprises at least four repeats of SEQ ID NO: 47.

33.-36. (Canceled)

37. (Currently Amended) The fusion protein of claim 3618, wherein the cell surface protein is CD20.

38. (Previously Presented) The fusion protein of claim 18, wherein said first polypeptide comprises at least amino acids 38 to 174 of streptavidin, as set forth in SEQ ID NO: 2.

39. (Currently Amended) The fusion protein of claim 18, wherein the first polypeptide comprises at least amino acids selected from the group consisting of: 25 to 182, 29 to 182, 38 to 174, 38 to 175, 38 to 176, 38 to 177, 38 to 178, 38 to 179, 38 to 180, 38 to 181, or and 38 to 182 of streptavidin, as set forth in SEQ ID NO: 2.

40.-64. (Canceled)

65. (Currently Amended) A composition, comprising the fusion protein of any one of claims 18-22, 24-32 and 37-39 and 24-39.